163 related articles for article (PubMed ID: 25560278)
1. Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.
Mitchell N; Fong PC; Broom RJ
Asia Pac J Clin Oncol; 2015 Sep; 11(3):e1-5. PubMed ID: 25560278
[TBL] [Abstract][Full Text] [Related]
2. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
Raphael J; Thawer A; Bjarnason GA
Urol Oncol; 2018 Jan; 36(1):12.e1-12.e6. PubMed ID: 28966072
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.
Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e45-e49. PubMed ID: 28429452
[TBL] [Abstract][Full Text] [Related]
6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
7. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review.
Zhang X; Shen P; Yao J; Chen N; Liu J; Zeng H
Medicine (Baltimore); 2018 Aug; 97(31):e11565. PubMed ID: 30075524
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
Tan HS; Li H; Hong YW; Toh CK; Wong A; Lopes G; Tay MH; Chan A; Yao X; Tang T; Ng QS; Kanesvaran R; Chau NM; Tan MH
Clin Genitourin Cancer; 2015 Aug; 13(4):e285-e295. PubMed ID: 25541325
[TBL] [Abstract][Full Text] [Related]
12. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
14. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
16. [A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Cui C; Li S; Chi Z; Si L; Sheng X; Mao L; Lian B; Wang X; Tang B; Guo J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):375-8. PubMed ID: 26463030
[TBL] [Abstract][Full Text] [Related]
17. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Suo A; Iqbal U; Lim J; Lee C; Gesy K; Iqbal N; Abbas T
Clin Genitourin Cancer; 2017 Jun; 15(3):e397-e404. PubMed ID: 28216279
[TBL] [Abstract][Full Text] [Related]
19. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
